Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results

Abstract

Background: Anti-HER2 agents were a breakthrough in the treatment of HER2- enriched breast cancer (BC). In this study, we aimed to describe the real-life efficacy and safety of pertuzumab-trastuzumab-taxane (PTT) combination in BC patients. Method(s): This study was conducted by the Turkish Oncology Group and reached 35 centers nationwide. 309 visceral metastatic, and trastuzumab naive patients who received first line PTT were included. Result(s): Patients' characteristics and treatment details are summarized in the table. Median progression-free survival (PFS) was 28.5 months (95% CI:15.6-41.4), while median overall survival (OS) was 40.3 months (95%CI: 26.9-53.7). Brain metastatic patients (n=13, 4.2%) had worse PFS (16.8m vs. 28.5m; HR:3.9, 95% CI:1.7-9.2, p=0.002) and OS (26.7m vs. 40.3m; HR:3.2, 95% CI:1.3-7.6, p=0.009). Elderly patients (>65y) had significantly lower OS results (19.8m vs. 40.3m; HR:0.4, %95 CI:0.2-0.8, p=0.01). Docetaxel was the choice in 268 patients (86.7%), while 41 patients (13.3%) received paclitaxel. There was no statistically significant difference in PFS (28.5mvs. 24.1 m; p=0.61) and OS (40.3mvs. NR; p=0.17) between taxane groups. Additionally,